Status:
COMPLETED
Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients
Lead Sponsor:
AstraZeneca
Conditions:
Gastroesophageal Reflux Disease (GERD)
Eligibility:
All Genders
17-70 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to estimate the effect of AZD3355 as an add-on treatment to a Proton Pump Inhibitor (PPI) on Gastroesophageal reflux disease (GERD) symptoms in patients with an incomplete...
Eligibility Criteria
Inclusion
- Provision of written informed consent
- At least 6 months history of Gastroesophageal reflux disease (GERD) symptoms
- Continuous treatment with Proton Pump Inhibitor (PPI)
- Ability to read and write
Exclusion
- Prior surgery of the upper gastrointestinal (GI) tract
- History of clinically significant diseases other than GERD
- Need for concomitant medication with drugs that may influence gastrointestinal symptoms
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2007
Estimated Enrollment :
244 Patients enrolled
Trial Details
Trial ID
NCT00394472
Start Date
November 1 2006
End Date
June 1 2007
Last Update
March 18 2013
Active Locations (38)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Adelaide, Australia
2
Research Site
Brussels, Belgium
3
Research Site
Eupen, Belgium
4
Research Site
Wilrijk, Belgium